TOKYO, Japan — January 9, 2025 — MOLCURE Inc. (headquartered in Kawasaki City, Kanagawa Prefecture, President: Satoshi Tamaki, hereafter “MOLCURE”) today announced that it has signed a joint research agreement with Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business. This agreement aims to use MOLCURE’s AI-driven drug discovery platform technology to develop innovative antibody drugs for central nervous system diseases.
Under the terms of the agreement, MOLCURE will use its proprietary AI-driven drug discovery platform system, which is built around a large-scale language model specifically developed for antibodies, to tackle optimization challenges for lead antibodies identified by Teijin Pharma. MOLCURE will receive research funding and milestone payments from Teijin Pharma based on R&D progress.
“We are delighted that Teijin Pharma has chosen MOLCURE as a partner, recognizing our AI technology’s ability to deliver results using limited data,” said Satoshi Tamaki, CEO of MOLCURE Inc. “We are excited to have this opportunity to use our AI-driven platform technology to significantly advance Teijin Pharma’s drug discovery program. I hope that our partnership will lead to new treatments that improve the prognosis and quality of life for patients worldwide.”
About MOLCURE
MOLCURE Inc. is a leader in AI-driven drug discovery for antibodies and peptides. Our platform combines cutting-edge large language models (LLMs), physics-based simulations, and high-quality experimental data from our in-house labs. This approach enables the discovery of innovative biologics that are safer and more effective, making it possible to tackle undrugged targets that other technologies cannot reach. We work with forward-thinking partners, including leading pharmaceutical companies, to accelerate R&D and help bring life-changing new treatments for patients around the world. Founded in 2013, MOLCURE is based in Japan, with headquarters in Kawasaki and a research facility in Tsuruoka.
Learn more at https://molcure.com.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan’s first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people in 20 countries. Teijin is committed to its Purpose, “Pioneering solutions together for a healthy planet.” Teijin works together with employees and external partners to achieve its Long-Term Vision, “To be a company that supports the society of the future.” Teijin posted consolidated sales of JPY 1,032.8 billion (USD 6.6 billion) and total assets of JPY 1,251.0 billion (USD 8.0 billion) in the fiscal year ending March 31, 2024.
Visit www.teijin.com
Media Contact:
Name: Kazu Inabe, Ph.D.
Email: contact[at]molcure.io
